- 1Medical Radiology Department, Tianjin Chest Hospital, Tianjin, China
- 2LinkDoc Technology, Beijing, China
- 3Tianjin Cardiovascular Institute, Tianjin Chest Hospital, Tianjin, China
- 4Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China
- 5Pathology Department, Tianjin Chest Hospital, Tianjin, China
Introduction: To evaluate the value of artificial intelligence (AI)-assisted software in the diagnosis of lung nodules using a combination of low-dose computed tomography (LDCT) and high-resolution computed tomography (HRCT).
Method: A total of 113 patients with pulmonary nodules were screened using LDCT. For nodules with the largest diameters, an HRCT local-target scanning program (combined scanning scheme) and a conventional-dose CT scanning scheme were also performed. Lung nodules were subjectively assessed for image signs and compared by size and malignancy rate measured by AI-assisted software. The nodules were divided into improved visibility and identical visibility groups based on differences in the number of signs identified through the two schemes.
Results: The nodule volume and malignancy probability for subsolid nodules significantly differed between the improved and identical visibility groups. For the combined scanning protocol, we observed significant between-group differences in subsolid nodule malignancy rates.
Conclusion: Under the operation and decision of AI, the combined scanning scheme may be beneficial for screening high-risk populations.
Introduction
In 2018, the American Cancer Society reported that the worldwide incidence and mortality rates were higher for lung cancer than for any other form of cancer (1). Early diagnosis and treatment are essential for improving survival and reducing mortality among patients with lung cancer. Although low-dose computed tomography (LDCT) screening for lung cancer has been validated in several randomised controlled trials (2, 3), this method is not without limitations, including a high false-positive rate (2). In clinical practice, the high false-positive rate is related to the relatively poor ability of LDCT to reveal fine structural details within lesions, compared to high-resolution computed tomography (HRCT) (4). For many patients with positive LDCT findings, diagnostic evaluations may yield uncertain results, in turn leading to uncertainty regarding long-term treatment strategies, increasing patient anxiety and resulting in an inefficient allocation of medical resources (5).
HRCT (4) can significantly improve the visualisation of fine structural details. Thus, LDCT, combined with HRCT of local lung nodules, may compensate for the deficiencies of LDCT in lung cancer screening. However, to our knowledge, no previous studies have investigated the types of lung nodules or patient subgroups in which this combined scanning strategy may be effective. Furthermore, the lack of a diagnostic protocol for combined scanning forces physicians to rely on subjective judgments when recommending HRCT.
Continued advancements in artificial intelligence (AI) may aid clinicians in detecting and diagnosing lung nodules (6, 7). In the present study, we utilised AI to assist in diagnosing lung nodules during LDCT. Lung nodules were analysed in real time via AI-assisted software, and the system recommended further local HRCT target scans in cases of highly suspicious nodules.
Materials and Methods
From September 2019 to December 2019, 815 patients underwent LDCT screening for lung nodules at our hospital. During inspiratory breath-hold acquisition, the apex to the bottom of the lungs was scanned. The images were observed using lung windows (window width: 1,600 HU, window level: −550 HU) and through the AI-assisted diagnostic system to determine the subsequent scanning scheme (Figure 1). AI calculated the LDCT images in real time, and the time was about two minutes. All the pulmonary nodules were found and sorted according to the maximum diameter of the nodules (Figure 2). These examiners further evaluated images from patients with lung nodules exhibiting a maximum diameter of ≥5 mm using the combined imaging strategy. According to this protocol, the entire lung was scanned using conventional-dose CT, and the largest lesions were scanned using local HRCT (Supplementary Figure 1). Patients with no lung nodules measuring ≥5 mm in diameter were scanned using LDCT only.
Figure 1 The flow chart shows the method designed to check the pulmonary nodules by AI calculation and to use the maximum diameter to carry out local targeted HRCT. In a later statistical analysis, we found that subsolid nodule and nodules with a malignant rate >39.50% were more visible with this method. We should determine whether to carry out local target scanning according to the malignant rate of subsolid nodules in order to guide the future LDCT screening with real-time AI pulmonary nodule detection.
Figure 2 Screenshot of AI-assisted diagnostic software in the analysis of a specific CT image. The long arrow shows the analysis of an LDCT image in which all detected nodules have been marked. The short arrow indicates detailed information regarding the underlying nodule (e.g., location, maximum diameter, minimum diameter, density type, malignancy probability, volume, mean CT value). AI, artificial intelligence; LDCT, low-dose computed tomography; CT, computed tomography.
In this study, 113 patients exhibited pulmonary nodules with a maximum diameter of ≥5 mm (43 men, 70 women; mean age: 65.6 ± 8.54 years; age range: 50–82 years). The ethics committee of our institution approved the study. Patients provided written informed consent before the examination. The work described was carried out in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.
Scanning Parameters
Images were obtained using a multi-slice CT (MSCT) scanner (Philips Brilliance, iCT 256). The following parameters were used for LDCT scans: tube voltage, 100 kV; tube current, 30, 40, or 50 mAs based on body mass index (BMI) values for each patient (BMI <18.5 kg/m2, BMI ≤18.5–≤25 kg/m2, BMI >25 kg/m2); reconstruction, iDose4; filter, lung enhanced; field of view (FOV), 350 mm; layer spacing, 1.5 mm; layer thickness, 1.5 mm; pitch, 0.758; rotation time, 0.5 s; reconstruction matrix, 512 × 512. For conventional-dose CT scans of pulmonary nodules, the tube voltage was set to 120 kV, the tube current was set to 100–250 mAs and the standard reconstruction setting was used. All other parameters were the same as those used for LDCT. Parameters for HRCT target scanning were as follows: tube voltage, 120 kV; tube current, 190–330 mAs; reconstruction, iDose3; filter, Y-Sharp; FOV, 150 mm; pitch, 0.399; rotation time, 0.33 s. The remaining HRCT parameters were the same as those used for LDCT.
The AI-assisted diagnostic system for lung nodules is commercially available. The data were retrieved from the Luna, NSCL and LIDC open datasets, as well as from 18 cooperative hospitals. All data were used for training of the AI system. The detection effect was verified on the Luna dataset (area under the free-response receiver operating characteristic [ROC] curve, 0.8612), while benign and malignant rates were verified on the DSB 2017 dataset (area under the curve [AUC], 0.89). The AI system consists of two modules: a detection module and a segmentation module (8). The detection module outputs the predicted nodule with a 3-D bounding box and nodule malignancy. The backbone of the detection module is a 3-D U-Net, and the output feature map is passed to a region proposal network for bounding box and malignancy prediction (9). The network is trained by backpropagation with the stochastic gradient descent optimiser. Based on the bounding box, the region of interest of detected nodules is calculated and passed to the nodule segmentation module (10), which outputs a reconstructed 3-D nodule mask for each detected nodule. Morphological features, such as the longest diameter, shortest diameter and volume of the nodule with the largest cross-sectional area, are calculated based on the output 3-D mask.
All CT images were obtained by two physicians with 11 and 17 years of experience in diagnosing chest images, respectively. Then, the images were examined in a double-blinded manner by two experienced radiologists. A senior imaging physician with 17 years of experience provided the final diagnosis in case of a disagreement between the two radiologists. All lung nodules were categorised as solid or subsolid nodules (including pure ground-glass nodules [GGN] and part-solid GGNs) according to lesion density. CT images were subjectively evaluated based on the following features: 1) the presence of lobulations, defined as deeper notches at the edges of tumours; 2) the presence of spiculations, defined as fine, short, unbranched opacities radiating from the edges of the tumour to surrounding areas; 3) the presence of abnormal air bronchograms (11) (i.e. narrowing, dilation, tortuous or separation of bronchi within the nodule); 4) the presence of a necrotic cavity within the lesion and discharge of necrotic tissue through the bronchus; 5) the presence of air-containing spaces (12), reflecting the pathological expansion of the physiological cavity in the lung; 6) the presence of single or multiple bubble-like lucencies (13) (i.e. 1–2 mm dot-like translucent shadows within the lesion); 7) the presence of pleural indentation in the case of pleural involvement.
Patients for whom the difference between the number of signs on the target HRCT and the conventional image was >1 were included in the improved visibility group (i.e. more signs observed during target scanning). The remaining patients were assigned to the identical visibility group.
Statistical Analyses
Stata version 14.1 (StataCorp, College Station, TX, USA) was used to perform statistical analyses. Continuous variables with a skewed distribution were expressed as medians and quartiles, while categorical data were expressed as rates or percentages. Wilcoxon rank-sum tests were used to compare continuous variables with skewed distributions. Kruskal–Wallis tests were used to compare data across multiple groups, while chi-square tests were used to compare data between groups. Univariate and multivariate logistic regression analyses were performed to determine the clear odds ratio (OR) of the target scan. All tests were two-tailed, and the level of statistical significance was set to a p value of <0.05. ROC curves were generated using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA). GraphPad Prism 7.0 was also used to calculate the AUC and determine the optimal cut-off values for low-dose volume and malignancy rate.
Results
Among the 815 physical examinations, 113 were selected for further screening. Total radiation doses were significantly lower for LDCT combined with local HRCT than for conventional-dose CT (358.93 vs. 473.67, p < 0.01) (Supplementary Table 1).
Among the 113 included cases, the largest lesions were classified as solid in 66 cases and subsolid in 47 cases. AI-assisted software was then used to determine the number of lung nodules detected via LDCT and conventional-dose CT. All lung nodules, not only the largest lesions detected by the software in the target scan, were divided into three groups based on maximum diameter: <5, 5–10 and >10 mm. Significantly fewer nodules with a diameter of <5 mm were detected by the AI system during the combined imaging scheme than during conventional-dose CT (p = 0.000) (Supplementary Table 2). However, no such differences were observed in the 5–10 or >10 mm groups (p > 0.05).
Following the aforementioned procedures, the AI-assisted software was used to identify the largest lesions in each of the 113 included patients (Figure 2). No significant differences in maximum diameter, volume or malignancy probability were observed between the combined scanning scheme and the conventional scanning scheme (p > 0.05) (Supplementary Table 3).
Supplementary Table 4 shows the results of subjective evaluations of the largest lesions in the 113 patients. When the three scanning methods were compared for subsolid nodules, we observed significant differences in the presence of air bronchogram abnormalities (Figure 3) and bubble-like lucencies (Figure 4) (p < 0.05).
Figure 3 A 55-year-old female patient with ground-glass nodules in the posterior segment of the right upper lobe detected by LDCT screening. AI indicated that the malignant rate was 97.46%. Surgical resection revealed invasive mural adenocarcinoma. CT images reconstructed by lung window. (A) LDCT image. The white arrow indicates that there is an obscure air bronchogram in the nodule. (B) Conventional CT image. The white arrow indicates a slightly clear air bronchogram in the nodule. (C) HRCT local-target scanning image. An abnormal air bronchogram is visible. The white arrow indicates that the target scan shows a finer tortuous bronchial sign. (D) Pathological HE staining image (×40) showing diffuse tumour tissue around bronchioles, infiltration and growth of tumour tissue, and proliferation of fibrous connective tissue (arrowheads), resulting in bronchiectasis (arrows). AI, artificial intelligence; LDCT, low-dose computed tomography; CT, computed tomography; HRCT, high-resolution computed tomography.
Figure 4 A 61-year-old female patient with ground-glass nodules in the posterior segment of the right upper lobe detected by LDCT screening. AI indicated that the malignant rate was 60.65%. Surgical resection revealed invasive mural adenocarcinoma. CT images reconstructed by lung window. (A) LDCT image. The white arrowheads indicate GGNs. (B) Conventional CT image. The white arrow indicates small bubble-like lucencies with unclear boundaries. (C) HRCT local-target scanning image. The white arrows indicate several bubble-like lucencies with clear boundaries. (D) Pathological HE staining image (×40) showing the destruction and fusion of two bubble-like lucencies (arrowheads) in the middle of the background of invasion and growth of tumour tissue. AI, artificial intelligence; LDCT, low-dose computed tomography; GGN, ground-glass nodule; HRCT, high-resolution computed tomography.
For solid nodules, our single-factor analysis revealed no statistically significant differences in maximum diameter, volume or malignancy probability between the improved visibility and identical visibility groups (Table 1). In addition, we observed no significant differences in the maximum diameter of subsolid nodules between the improved visibility and identical visibility groups. However, for subsolid nodules, there were significant differences in volume (474.54 [283.19, 1,599.08] vs. 306.40 [171.40, 489.26] mm3, p < 0.05) and malignancy probability (55.96% vs. 12.8%, p < 0.01) between the improved visibility and identical visibility groups. The classification model based on volume and malignancy probability accurately predicted whether the local-target scanning via HRCT could improve the visibility of subsolid nodules (Figure 5).
Figure 5 ROC analysis of the prediction model for improved visibility. ROC, receiver operating characteristic; AUC, area under the ROC curve. p < 0.05.
Multiple logistic regression analyses (Table 2) yielded cut-off values of >347.7 mm3 for subsolid nodule volume and >39.50% for malignancy rates. For the combined scanning scheme, we observed significant differences in malignancy probability between the improved visibility and identical visibility groups (OR = 6.885, 95% confidence interval (CI): 1.595–29.713, p = 0.010). For a malignancy probability of >39.50%, sensitivity and specificity values were 66.67% and 82.61%, respectively.
Table 2 Multivariate analysis of subsolid nodule findings in the improved visibility and identical visibility groups.
Discussion
Previous studies offer evidence showing that in selected high-risk groups, LDCT examination can significantly reduce lung cancer mortality (14, 15). During LDCT, radiation dosages are reduced by decreasing the tube current and voltage. However, decreasing the X-ray doses also affects the signal-to-noise ratio, in turn impacting the visualisation of fine structures within lung nodules. The ability to visualise certain fine structures within lung nodules is essential for an accurate diagnosis.
Previous LDCT studies (15, 16) have focused on optimising the risk-reward ratio by reducing tube current or improving image reconstruction algorithms. However, such developments have been associated with only marginal improvements in the assessment of malignancy in high-risk nodules, as accurate diagnosis requires high-resolution images, which cannot be obtained via LDCT. In contrast to LDCT and conventional-dose CT, HRCT allows the visualisation of microstructures within high-risk nodules. Indeed, we observed a significant difference in the presence of air bronchogram abnormalities and bubble-like lucencies in subsolid nodules between the LDCT and HRCT conditions (p < 0.05). Compared with conventional CT local-target reconstruction, HRCT target scanning has several advantages, such as small geometric distortion, improved density and spatial resolution, higher contrast and sharper edges of tiny structures, due to its unique algorithm (4, 17). The imager can obtain more information when observing the microscopic structure of minor lesions on account of the abovementioned advantages of HRCT target scanning. However, considering the above-average radiation doses (4), chest HRCT is not recommended in low-risk cases. In the present study, we utilised a combined LDCT/HRCT scanning strategy to investigate highly suspicious lung nodules identified via an AI-assisted system. Our combined scanning strategy of using AI-assisted diagnostic software to target high-risk locations systematically during HRCT represents an ideal approach in which excessive radiation doses are allocated to high-risk locations only and achieves the best possible trade-off between accuracy/specificity and total radiation dose.
In the present study, total radiation doses were significantly lower for the AI-optimised combined scanning scheme than for the conventional scanning scheme (p < 0.01), suggesting that the combined scanning scheme is no more harmful to the patient than conventional-dose scanning. In addition, the number of nodules measuring <5 mm in diameter detected by the AI-assisted software was significantly lower in the LDCT condition than in the conventional-dose condition (p < 0.01). This finding suggests that, due to the low quality of the images produced by LDCT, the sensitivity of the AI-assisted software for detecting nodules measuring <5 mm in diameter was reduced, consistent with the results of visual examination. However, we observed no significant differences in detection sensitivity for nodules of 5–10 or >10 mm between LDCT and conventional-dose scanning (p > 0.05). Considering that previous studies have reported that nodules with diameters of <5 mm do not warrant a long-term follow-up (18), reduced sensitivity for these nodules is less likely to affect clinical diagnosis. Furthermore, we observed no significant differences in maximum diameter, volume or malignancy rates between the combined and conventional scanning strategies for nodules measuring 5–10 and >10 mm in diameter (p > 0.05). These results indicated that our AI-optimised combined scanning strategy is likely to achieve performance similar to conventional scanning.
The present study also investigated the types of nodules for which HRCT is sensitive. In this case, we defined ‘sensitivity’ as the ability of HRCT to identify more clinical characteristics of subsolid nodules, including the presence of air bronchograms and bubble-like lucencies. The present study was based on the underlying principle that additional radiation doses should be allocated to locations where HRCT can reveal significantly more information than LDCT or conventional-dose scanning. When there was insufficient statistical evidence to suggest that HRCT could yield such information, we opted to perform local HRCT on those locations. For the 66 solid nodules, we observed no significant difference in maximum diameter, volume or malignancy probability (p > 0.05). Solid nodules rarely exhibit hollow microstructures such as abnormal air bronchograms, bubble-like lucencies or air-containing spaces, considering their density. In addition, boundary-related features, such as lobulations, spiculations and pleural indentation signs, can be detected using conventional CT in cases wherein the amount of information gained using HRCT is insignificant. In contrast, subsolid nodules are correlated with the presence of hollow microstructures.
Consistent with the findings of previous studies, our results indicated that HRCT was associated with significantly better visualisation of these hollow microstructures than conventional CT (4). The results of our multivariate analysis indicated that a malignancy probability of >39.50% for subsolid nodules was associated with improved visibility on HRCT (subjective visual information gain: 6.885 x [p < 0.05], sensitivity: 66.67%, specificity: 82.61%). Our results suggest that HRCT local-target scanning should be recommended when AI-assisted LDCT identifies a subsolid nodule with a malignancy probability of >39.50%. HRCT local-target scanning is not recommended in these cases, considering the limited amount of information gained for other types of nodules.
The present study has some limitations of note. First, our investigation was not based on solid pathological evidence; interpretations of HRCT images were based on subjective assessments by physicians, and the estimated cut-off values determined using proprietary AI-assisted software were dependent on the version of the software. Second, our study included a small sample of 113 patients, necessitating larger follow-up studies to verify our findings.
Our combined scanning strategy was associated with significant decreases in radiation dose relative to conventional scanning, without significant changes in detection count, size or malignancy probability for high-risk nodules (nodules measuring ≥5 mm in diameter). Furthermore, our results demonstrate that performing HRCT local-target scanning for LDCT-identified subsolid nodules with a malignancy probability of >39.50% provides the optimal balance between improved visualisation and decreased radiation doses. This combined strategy may be suitable for the practical application of pulmonary nodule screening.
In summary, the combined scanning scheme is conducive to screening high-risk pulmonary nodules in the population. The application of AI can predict in which pulmonary nodules to implement this scheme, which is highly targeted and has more advantages than previous subjective evaluation. In addition, the application of AI can reduce unnecessary radiation doses and improve the visibility of fine structure within small nodules.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics Statement
The studies involving human participants were reviewed and approved by Medical Ethics Committee of Tianjin Chest Hospital. The patients/participants provided their written informed consent to participate in this study.
Author Contributions
Guarantor of integrity of the entire study: JuL. Study concept and design: HZ. Literature research: JiL, ZS, and YG. Clinical studies: GZG, SL and XML. Experimental studies/data analysis: GMG and YY. Statistical analysis: MR. Manuscript preparation: YJ and YL. Manuscript editing: XFL and YM. All authors contributed to the article and approved the submitted version.
Funding
This project was supported by Grant No. 18ZXZNSY00400 from the Tianjin Science and Technology Plan Project on the construction of data platforms for artificial intelligence-assisted diagnosis of lung nodules and clinical applications of such systems in the diagnosis and treatment of lung cancer.
Conflict of Interest
Authors XFL, GMG and YJ were employed by company LinkDoc Technology.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We would like to thank Editage (www.editage.com) for English language editing.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.749219/full#supplementary-material
Supplementary Figure 1 | The left side of the image is the whole lung field LDCT scan (arrows), and the right side is the local HRCT scan for the largest lesion (arrowheads). Total radiation doses were significantly lower for LDCT combined with local HRCT than for conventional-dose CT (358.93 vs 473.67, p < 0.01, n=113).
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 1168(6):394–424. doi: 10.3322/caac.21492
2. Moyer VA, Moyer VA, LeFevre ML, Siu AL, Peters JJ, Baumann LC, et al. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med (2014) 160(5):330–8. doi: 10.7326/M13-2771
3. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced Lung-Cancer Mortality With Low-Dose Computed Tomographic Screening. N Engl J Med (2011) 365(5):395–409. doi: 10.1056/NEJMoa1102873
4. Zhu Y, Hou D, Lan M, Sun X, Ma X. A Comparison of Ultra-High-Resolution CT Target Scan Versus Conventional CT Target Reconstruction in the Evaluation of Ground-Glass-Nodule-Like Lung Adenocarcinoma. Quant Imaging Med Surg (2019) 9(6):1087–94. doi: 10.21037/qims.2019.06.09
5. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, et al. The American Association for Thoracic Surgery Guidelines for Lung Cancer Screening Using Low-Dose Computed Tomography Scans for Lung Cancer Survivors and Other High-Risk Groups. J Thorac Cardiovasc Surg (2012) 144(1):33–8. doi: 10.1016/j.jtcvs.2012.05.060
6. Zhang C, Sun X, Dang K, Li K, Guo XW, Chang J, et al. Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network. Oncologist (2019) 24(9):1159–65. doi: 10.1634/theoncologist.2018-0908
7. Ather S, Kadir T, Gleeson F. Artificial Intelligence and Radiomics in Pulmonary Nodule Management: Current Status and Future Applications. Clin Radiol (2020) 75(1):13–9. doi: 10.1016/j.crad.2019.04.017
8. Liu X. Deep Learning Analysis for Automatic Lung Nodule Detection. J Global Oncol (2019) 5:27. doi: 10.1200/JGO.2019.5.suppl.27
9. Liao F, Liang M, Li Z, Hu X, Song S. Evaluate the Malignancy of Pulmonary Nodules Using the 3-D Deep Leaky Noisy-OR Network. IEEE Trans Neural Netw Learn Syst (2019) 30(11):3484–95. doi: 10.1109/TNNLS.2019.2892409
10. Bonavita I, Rafael-Palou X, Ceresa M, Piella G, Ribas V, González Ballester MA. Integration of Convolutional Neural Networks for Pulmonary Nodule Malignancy Assessment in a Lung Cancer Classification Pipeline. Comput Methods Programs Biomed (2020) 185:105172. doi: 10.1016/j.cmpb.2019.105172
11. Dai J, Shi J, Soodeen-Lalloo AK, Zhang P, Yang Y, Wu C, et al. Air Bronchogram: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Subsolid Nodules. Lung Cancer (2016) 98:22–8. doi: 10.1016/j.lungcan.2016.05.009
12. Nambu A, Miyata K, Ozawa K, Miyazawa M, Taguchi Y, Araki T. Air-Containing Space in Lung Adenocarcinoma: High-Resolution Computed Tomography Findings. J Comput Assist Tomogr (2002) 26(6):1026–31. doi: 10.1097/00004728-200211000-00030
13. Liu Y, Kim J, Qu F, Liu S, Wang H, Balagurunathan Y, et al. CT Features Associated With Epidermal Growth Factor Receptor Mutation Status in Patients With Lung Adenocarcinoma. Radiology (2016) 280(1):271–80. doi: 10.1148/radiol.2016151455
14. Wender R, Fontham ET, Barrera E, Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society Lung Cancer Screening Guidelines. CA Cancer J Clin (2013) 63(2):107–17. doi: 10.3322/caac.21172
15. Takahashi H, Okada M, Hyodo T, Hidaka S, Kagawa Y, Matsuki M, et al. Can Low-Dose CT With Iterative Reconstruction Reduce Both the Radiation Dose and the Amount of Iodine Contrast Medium in a Dynamic CT Study of the Liver. Eur J Radiol (2014) 83(4):684–91. doi: 10.1016/j.ejrad.2013.12.014
16. Gordic S, Morsbach F, Schmidt B, Allmendinger T, Flohr T, Husarik D, et al. Ultralow-Dose Chest Computed Tomography for Pulmonary Nodule Detection: First Performance Evaluation of Single Energy Scanning With Spectral Shaping. Invest Radiol (2014) 49(7):465–73. doi: 10.1097/RLI.0000000000000037
17. Yasaka K, Katsura M, Hanaoka S, Sato J, Ohtomo K. High-Resolution CT With New Model-Based Iterative Reconstruction With Resolution Preference Algorithm in Evaluations of Lung Nodules: Comparison With Conventional Model-Based Iterative Reconstruction and Adaptive Statistical Iterative Reconstruction. Eur J Radiol (2016) 85(3):599–606. doi: 10.1016/j.ejrad.2016.01.001
18. Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, et al. Lung Cancer Probability in Patients With CT-Detected Pulmonary Nodules: A Prespecified Analysis of Data From the NELSON Trial of Low-Dose CT Screening. Lancet Oncol (2014) 15(12):1332–41. doi: 10.1016/S1470-2045(14)70389-4
Keywords: artificial intelligence-assisted diagnosis, low-dose radiation, pulmonary nodules, spiral computed tomography, target scan
Citation: Lv J, Li J, Liu Y, Zhang H, Luo X, Ren M, Gao Y, Ma Y, Liang S, Yang Y, Song Z, Gao G, Gao G, Jiang Y and Li X (2022) Artificial Intelligence-Aided Diagnosis Software to Identify Highly Suspicious Pulmonary Nodules. Front. Oncol. 11:749219. doi: 10.3389/fonc.2021.749219
Received: 29 July 2021; Accepted: 17 December 2021;
Published: 15 February 2022.
Edited by:
Wenyin Shi, Thomas Jefferson University, United StatesReviewed by:
Bilgin Kadri Aribas, Bülent Ecevit University, TurkeyXiaofen Xing, Shanxi Provincial Cancer Hospital, China
Copyright © 2022 Lv, Li, Liu, Zhang, Luo, Ren, Gao, Ma, Liang, Yang, Song, Gao, Gao, Jiang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hong Zhang, zhangh0ng@126.com